Who are Gain Therapeutics's investors?

Gain Therapeutics's investors include 3B Future Health Fund, TiVenture SA, Allele Capital Partners.

How much funding has Gain Therapeutics raised?

Gain Therapeutics has disclosed $10M raised across 1 of its 2 known rounds.

Where is Gain Therapeutics headquartered?

Gain Therapeutics is headquartered in Bethesda, US.

Gain Therapeutics

NASDAQ: GANX

Bethesda, US · Founded 2020 · 3 known investors

Find your way into Gain Therapeutics

Gain Therapeutics is a biotechnology company that develops small molecule drugs targeting allosteric binding sites on disease-related proteins, using its computational Magellan platform to discover compounds that stabilize or destabilize proteins to treat central nervous system disorders, lysosomal storage diseases, metabolic disorders, and oncology; its lead candidate GT-02287 is in Phase 1b testing for Parkinson's disease.

AI & Machine Learning Biotech Deep Tech Digital Health Medical Devices

Founders & leadership

Gene Mack inChief Executive OfficerGene Mack is President and Chief Executive Officer of Gain Therapeutics, a biotechnology company developing small molecule therapeutics. He has over 25 years of experience in life sciences, including roles in capital markets, investment banking, and corporate finance, with a background in M&A, IPO execution, and capital structuring.

Board

Marianne BjordalBoard directorGeneral Partner at 3B Future Health Fund

Lorenzo Leoni inCo-FounderFounder and Managing Director at Ti-Ventures

Khalid IslamBoard director

Jeffrey RileyBoard director

Eric I. RichmanBoard director

Investors · 3

3B Future Health FundMonaco · $12M

TiVenture SALugano

Allele Capital PartnersreportedFort Lauderdale

Reported raises · per SEC filings

Form D private placements

$10M disclosed across 1 of 2 rounds · 2019–2020

▶$10MraisedJul 2020 · 48 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Khalid IslamDirector
Marianne BjordalDirector
Jeffrey RileyDirector
Lorenzo LeoniDirector
Eric I. RichmanExecutive Officer, Director

Offering amount: $10M
Amount sold: $10M
Minimum investment: $50K
Sales commissions: $800K
Placement agents: Tribal Capital Markets, LLC
First sale: Jul 2020
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events

$84.6Mvaluation at IPOMar 2021 · $11.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Competitors · 1

by search overlap

Oup73 shared keywordsOxford University Press (OUP) provides dictionary data, language datasets, and lexical content in over 60 languages to power digital literacy tools, educational software, gaming platforms, and media experiences. The company works across reading apps, word games, quiz shows, and broadcast media to expand access to language learning and comprehension.

Companies competing with Gain Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

H.C. Wainwright reiterates Gain Therapeutics stock rating at buy By Investing.cominvesting.com · Aug 2026

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conferencefinance.yahoo.com · Aug 2026

Gain Therapeutics warns on going-concern amid cash burn | GANX Quarterly Report (10-Q)stocktitan.net · Aug 2026

Gain Therapeutics, Inc. Announces Close of $10 Million Series B Financing - Perspectives from Gain Therapeuticsgaintherapeutics.com · Jul 2020

Gain Therapeutics Raises $40M in IPO to Advance Rare Disease Pipeline - Perspectives from Gain Therapeuticsgaintherapeutics.com

Frequently asked questions

What does Gain Therapeutics do?: Gain Therapeutics is a biotechnology company that develops small molecule drugs targeting allosteric binding sites on disease-related proteins, using its computational Magellan platform to discover compounds that stabilize or destabilize proteins to treat central nervous system disorders, lysosomal storage diseases, metabolic disorders, and oncology; its lead candidate GT-02287 is in Phase 1b testing for Parkinson's disease.
Who are Gain Therapeutics's investors?: Gain Therapeutics's investors include 3B Future Health Fund, TiVenture SA, Allele Capital Partners.
How much funding has Gain Therapeutics raised?: Gain Therapeutics has disclosed $10M raised across 1 of its 2 known rounds.
Where is Gain Therapeutics headquartered?: Gain Therapeutics is headquartered in Bethesda, US.